Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Axsome Therapeutics on Monday reported data for two Phase 3 studies in Alzheimer’s-related agitation, saying one trial succeeded while the other failed. Researchers looked at whether an Axsome program called AXS ...